Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235.
D. Bottino
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. Tabernero
Consultant or Advisory Role - Novartis (U)
H. A. Burris
No relevant relationships to disclose
C. Britten
No relevant relationships to disclose
L. C. Chen
No relevant relationships to disclose
J. C. Bendell
Consultant or Advisory Role - Novartis
O. Chiparus
Employment or Leadership Position - Novartis
V. Duval
Employment or Leadership Position - Novartis
E. Di Tomaso
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
C. Sarr
Employment or Leadership Position - Novartis
W. Hackl
Employment or Leadership Position - Novartis
J. Baselga
Consultant or Advisory Role - Novartis
J. Rodon Ahnert
Research Funding - Novartis